Subscribe To Print Edition About The Tribune Code Of Ethics Download App Advertise with us Classifieds
search-icon-img
  • ftr-facebook
  • ftr-instagram
  • ftr-instagram
search-icon-img
Advertisement

Covaxin safe in 2 to 18-year-olds: Lancet

New Delhi, June 17 Indian vaccine maker Bharat Biotech’s Covaxin, the whole-virion inactivated Covid-19 vaccine, has proven to be safe, well-tolerated and highly immunogenic in paediatric subjects aged 2 to 18 years in Phase 2 and 3 studies. The...
  • fb
  • twitter
  • whatsapp
  • whatsapp
Advertisement

New Delhi, June 17

Indian vaccine maker Bharat Biotech’s Covaxin, the whole-virion inactivated Covid-19 vaccine, has proven to be safe, well-tolerated and highly immunogenic in paediatric subjects aged 2 to 18 years in Phase 2 and 3 studies.

Advertisement

The safety and efficacy study has been published in Lancet Infectious Diseases, a peer reviewed high impact factor journal.

The research shows Bharat Biotech conducted Phase II/III, open-label and multicentre study to evaluate the safety, reactogenicity and immunogenicity of Covaxin in healthy children and adolescents in 2-18 years of age group. The clinical trial in the paediatric population between June 2021 and September 2021 showed safety, less reactogenic and robust immunogenicity.

Advertisement

NTAGI for reducing booster dose gap

The National Technical Advisory Group on Immunisation has recommended reducing the gap between the second dose of the Covid vaccine and the booster dose from the current nine to six months. TNS

Advertisement
Advertisement
Advertisement
Advertisement
tlbr_img1 Home tlbr_img2 Opinion tlbr_img3 Classifieds tlbr_img4 Videos tlbr_img5 E-Paper